Ligand to Hold Investor and Analyst Day on December 13

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it will hold an Investor and Analyst Day at The St. Regis New York on December 13, 2022, from 11:00 a.m. to 12:30 p.m. Eastern time (8:00 a.m. to 9:30 a.m. Pacific time).

SAN DIEGO--( BUSINESS WIRE )-- Ligand Pharmaceuticals Inc. (NASDAQ: LGND) today announced that it will hold an Investor and Analyst Day at The St. Regis New York on December 13, 2022, from 11:00 a.m. to 12:30 p.m. Eastern time (8:00 a.m. to 9:30 a.m. Pacific time). A live and archived webcast will be available for those unable to attend in person. Presenters will include:

• John Higgins, Chief Executive Officer
• Matt Korenberg, President and Chief Operating Officer
• Tavo Espinoza, Chief Financial Officer
• Andrew Reardon, Chief Legal Officer
• Diane Retallack, Senior Vice President of Platform Technology and Innovation

Presentations by Ligand executives will address the following topics:

• Commentary on Ligand’s business model, financial outlook and capital deployment strategy
• Overview of Ligand’s technology platforms
• Overview of core partner and license assets
• Review of Ligand’s intellectual property and patent portfolio
• Discussion of Ligand’s commitment to ESG and ongoing corporate sustainability initiatives

The presentations will be followed by lunch for those attending in person. The live and archived webcast can be accessed here . For more information or make a reservation to attend, please contact Carolyn Curran at ccurran@lhai.com .

About Ligand Pharmaceuticals